Unigene Biotechnology

Unigene Biotechnology is a biopharmaceutical company based in China, originally established as a joint venture between the US-based Unigene Laboratories and CSPC Pharmaceutical Group. The company specializes in the development and manufacturing of peptide-based therapeutics using recombinant DNA technology and advanced oral delivery platforms, notably the Peptelligence technology. Following its full acquisition by CSPC Pharmaceutical Group, the company serves as a key unit for the group's biologics and peptide drug development. Its portfolio includes recombinant salmon calcitonin and parathyroid hormone (PTH) analogs, focusing on metabolic bone diseases and other conditions requiring peptide therapy.